​Judge rejects Amgen bid to stop biosimilar drug

A federal judge has denied Amgen’s Inc.’s request to temporarily halt the sale of Novartis AG’s biosimilar cancer drug recently approved by the Food and Drug Administration. Earlier this month, the FDA approved Zarxio, Novartis’ version of Amgen’s Neupogen cancer drug, the first time the agency has approved a biosimilar drug in the U.S. The approval clears the way for various drugmakers to pursue the manufacture of biosimilar medicines, which can cost 20 to 30 percent less than the original…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news